-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Aligos Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2020 to Q2 2024.
- Aligos Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $189K, a 75% decline year-over-year.
- Aligos Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $212K, a 73.6% decline year-over-year.
- Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $795K, a 650% increase from 2022.
- Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $106K, a 25.9% decline from 2021.
- Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $143K, a 11.2% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)